Pfizer and U.S. settle Bextra, other probes

Pfizer Inc., the drugmaker that yesterday said it would acquire rival Wyeth for $68 billion, took a $2.3 billion charge for a record settlement of U.S. investigations into improper marketing of its Bextra painkiller and other drugs.